Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial
Most events are mild to moderate, occur during escalation, and diminish over time
Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy
GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet cells, promotion of islet cell proliferation, and minimal side effects
Doctors can also help set realistic goals and explain the possible benefits and risks
GLP-1 receptor agonists and disordered eating: A systematic review of risks and therapeutic potential